Table 2 Baseline demographic, clinicopathologic, treatment characteristics and follow-up data according to subgroups

Female(%)

30 (29.7%)

162 (38.8%)

74 (37.2%)

0.239

Age (y, mean ± SD)

60.9(±9.27)

63.2(±8.797)

61.7(±8.21)

0.011

BMI (kg/m [2], mean ± SD)

22.8(±2.76)

22.6(±3.30)

22.8(±2.81)

0.413

WBC(^a10^{^9}/L, mean ± SD)

6.3(±2.42)

5.9(±2.07)

6.2(±1.88)

0.063

Neutrophil(^a10^{^9}/L, mean ± SD)

7.4(±14.79)

5.4(±10.00)

7.7(±14.34)

0.130

Lymphocyte(^a10^{^9}/L, mean ± SD)

1.6(±1.03)

1.4(±0.55)

1.5(±0.49)

0.143

Monocyte(^a10^{^9}/L, mean ± SD)

0.4(±0.18)

0.4(±0.42)

0.5(±0.20)

0.001

RBC(^a10^{^12}/L, mean ± SD)

4.3(±0.54)

4.1(±0.55)

4.2(±0.59)

0.001

Albumin(g/L, mean ± SD)

39.6(±4.24)

39.1(±5.74)

38.2(±4.85)

0.085

LMR

5.1(±9.10)

4.2(±5.78)

3.63(±1.51)

0.774

PLR

161.3(±111.80)

158.3(±84.96)

147.5(±67.84)

0.549

NLR

6.7(±16.25)

4.5(±9.12)

5.5(±10.72)

0.831

SIRI

2.5(±5.40)

2.0(±4.47)

2.6(±4.99)

0.118

CA199 (U/mL, median with IQR)

356.0 (96.2–1319.2)

170.3 (46.6–630.3)

102.4 (34.0–288.0)

< 0.0001

CA125(U/mL, median with IQR)

22.6 (12.4–35.0)

17.0 (11.4–30.0)

14.7 (9.4–23.7)

< 0.0001

CEA (ng/mL, median with IQR)

4.0 (2.3–6.8)

3.5 (2.2–6.2)

3.2 (1.8–6.6)

0.250

Borderline resectable

32 (31.7%)

114 (27.3%)

32 (16.1%)

0.002

Tumor size (cm, median with IQR)

3.5 (3.0–4.0)

3.0 (2.5–4.0)

3.0 (2.5–4.0)

< 0.0001

0.337

 Pancreaticduodenectomy

65 (64.4%)

270 (64.6%)

133 (66.8%)

 Distal pancreatectomy

30 (29.7%)

124 (29.7%)

62 (31.2%)

 Total pancreatectomy

6 (5.9%)

24 (5.7%)

4 (2.0%)

 Perioperative transfusion

74 (73.2%)

311 (74.4%)

160 (80.4%)

0.212

 Operation time (min, median with IQR)

300 (240–360)

300 (223.8–345)

270 (210–330)

0.055

 Bleeding amount (ml, median with IQR)

300 (200–600)

300 (200–500)

400 (200–500)

0.581

 Vascular resection

21 (20.8%)

69 (16.5%)

23 (11.6%)

< 0.0001

 R0 resection

88 (87.1%)

469 (87.5%)

79 (97.5%)

0.027

< 0.0001

 Well-moderate

23 (22.8%)

137 (32.8%)

107 (53.8%)

 Poor

78 (77.2%)

281 (67.2%)

92 (46.2%)

 Margin

1.4 (0.6–2.0)

1.0 (0.5–2.0)

1.0 (0.6–2.5)

0.687

0.006

 T1–2

66 (65.2%)

281 (67.2%)

157 (78.9%)

 T3–4

35 (34.7%)

137 (32.8%)

42 (21.1%)

0.006

 0

34 (33.7%)

184 (44.0%)

97 (48.7%)

 1

50 (49.5%)

164 (39.2%)

87 (43.7%)

 2

17 (16.8%)

70 (16.7%)

15 (7.5%)

 LNM

67 (66.3%)

234 (56.0%)

102 (51.3%)

0.045

 Harvested lymph nodes

13 (6–21)

13 (7–19)

10 (5.5–15.5)

0.421

 Number of LNM

1 (0–3)

1 (0–2)

0 (0–2.0)

0.019

 Positive lymph node ratio

0.09 (0–0.2)

0.06 (0–0.19)

0.04 (0–0.14)

0.019

 Perineural invasion

91 (90.1%)

398 (95.2%)

192 (96.53%)

0.199

0.010

  ≤ 2A

31 (30.7%)

254 (60.8%)

96 (48.2%)

 >2A

70 (69.3%)

164 (39.2%)

103 (51.8%)

0.267

  < 3

89 (88.1%)

351 (84.0%)

166 (83.4%)

  ≥ 3

1 (1.0%)

15 (3.6%)

10 (5.0%)

0.766

 Biochemical leak

52 (51.4%)

172 (41.4%)

92 (46.2%)

 Grade B/C POPF

16 (15.8%)

57 (13.6%)

25 (12.6%)

 Adjuvant chemotherapy

70 (69.3%)

288 (68.9%)

141 (70.9%)

0.160

 Gemcitabine

6 (5.9%)

37 (8.9%)

28 (14.1%)

 S-1 or Capecitabine

5 5.0%)

26 (6.2%)

13 (6.5%)

 Combined ^a

59 (58.4%)

225 (53.8%)

100 (50.2%)

< 0.0001

 Local

10 (9.9%)

72 (17.2%)

61 (30.7%)

 Systemic

67 (66.3%)

242 (57.9%)

81 (40.7%)

 Multiple

13 (12.9%)

49 (11.7%)

22 (11.1%)

 Not know

11 (10.9%)

55 (13.2%)

35 (17.6%)

 mDFS

1.3 (1.1–1.4)

6.4 (6.0–6.9)

18.5 (17.3–19.7)

< 0.0001

 mOS

9.8 (7.8–11.7)

14.7 (13.9–15.8)

30.8 (29.1–32.5)

< 0.0001

 Median total survival

12.5 (10.7–14.4)

16.7 (15.7–17.6)

35.1 (32.1–38.0)

< 0.0001